Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11148243.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.
Medical subject headings
- Immunosuppressive Agents
- Myasthenia Gravis
- Mycophenolic Acid